Articles from Nutriband Inc.
Nutriband Extends Chinese Patent to Macao for its AVERSA™ Abuse Deterrent Transdermal Technology
Nutriband’s abuse-deterrent platform technology is now patented in 46 countries and territories covering major global markets.
By Nutriband Inc. · Via GlobeNewswire · December 27, 2024
Nutriband Inc. Quarterly Report Highlights Record Revenue for Q3 up 50.94% YOY and Strategic Progress Toward NDA Filing for AVERSA Fentanyl in 2025
ORLANDO, Fla., Dec. 04, 2024 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQNTRB) NASDAQ:NTRBWNASDAQNTRBW)
By Nutriband Inc. · Via GlobeNewswire · December 4, 2024
Nutriband Inc. to Present at The 2024 Noble Conference in Boca Raton on December 4th
ORLANDO, Fla., Dec. 04, 2024 (GLOBE NEWSWIRE) -- Nutriband Inc. (Nasdaq:NTRB)(Nasdaq:NTRBW) today announced that it will be presenting at the Noble Conference taking place December 3rd and 4th at the Florida Atlantic University in Boca Raton, FL. Company President and Chairman Serguei Melnik will present at 1.30 PM in Conference room 3 on December 4th to primarily discuss the company’s AVERSA technology.
By Nutriband Inc. · Via GlobeNewswire · December 4, 2024
Nutriband Receives Hong Kong Patent Notice of Publication for Its Aversa™ Abuse Deterrent Transdermal Technology
AVERSA Fentanyl has the potential to be the world's first and only abuse-deterrent opioid patch
By Nutriband Inc. · Via GlobeNewswire · November 27, 2024
Nutriband Inc. Announces Seven-for-Six Forward Stock Split
By Nutriband Inc. · Via AccessWire · July 27, 2022
1.2M Shares of Nutriband Inc. to be Cancelled from Total Outstanding Shares Following Final Court Judgment in Favor of the Company
By Nutriband Inc. · Via AccessWire · July 26, 2022
Nutriband Inc. Registers New Company Branch in Ecuador with Plans to Expand into the South American Market
By Nutriband Inc. · Via AccessWire · July 22, 2022
Nutriband Inc. Successfully Obtains Court Verdict for Recovery of Shares Constituting 15% of Its Total Outstanding Shares
By Nutriband Inc. · Via AccessWire · July 15, 2022
Nutriband Supports Update to CDC Opioid Prescribing Guidelines
New proposed guidelines reiterate need for abuse deterrent technologies and call for enabling clinicians to provide comprehensive pain management including appropriate use of opioid medications
By Nutriband Inc. · Via AccessWire · June 3, 2022
Nutriband Inc. Interview to Air on Bloomberg U.S. on The Redchip Money Report(R)
By Nutriband Inc. · Via AccessWire · May 27, 2022
Nutriband Inc. to Present at the Emerging Growth Conference on May 25
Nutriband Inc. Invites Individual and Institutional Investors As Well as Advisors and Analysts, To Attend Its Real-Time, Interactive Presentation at the Emerging Growth Conference
By Nutriband Inc. · Via AccessWire · May 20, 2022
Nutriband Inc. Receives Orders for $230,000 in Contract Manufacturing for First 3 Weeks of May
By Nutriband Inc. · Via AccessWire · May 17, 2022
Nutriband Subsidiary Active Intelligence LLC Registers with FDA as a Medical Device Manufacturer for its AI Kinesiology Tape Product
Class 1 Medical Device Registration Allows Nutriband To Explore New Product Manufacturing Opportunities Through Its Wholly Owned Subsidiary Active Intelligence LLC ORLANDO, FL / ACCESSWIRE / May 11, 2022 / Nutriband Inc. (NASDAQNTRB)NASDAQ:NTRBWNASDAQNTRBW)
By Nutriband Inc. · Via AccessWire · May 11, 2022
Nutriband Inc. Reports Revenue Up 56% in Fiscal 2022 to a Record $1.4M
Our newswire features a comprehensive, flat-fee Press Release service. Generate quality engagement with real-time analytics to improve visibility and expand your influence.
By Nutriband Inc. · Via AccessWire · April 29, 2022
Nutriband Inc.'s Patent, 'Abuse and Misuse Deterrent Transdermal System’ Published by the United States Patent and Trademark Office Following Recent Issuance Notice
By Nutriband Inc. · Via AccessWire · February 16, 2022
Nutriband Inc. To Participate in The Benzinga All Access Event on February 4
By Nutriband Inc. · Via AccessWire · February 4, 2022
Nutriband Issued Full US Patent for Its Aversa(TM) Abuse Deterrent Transdermal Platform by United States Patent and Trademark Office
By Nutriband Inc. · Via AccessWire · January 28, 2022
Nutriband Inc. Expands Product Development Pipeline for Its AVERSA(TM) Platform Abuse Deterrent Technology
By Nutriband Inc. · Via AccessWire · January 18, 2022
Nutriband Inc. And Kindeva Drug Delivery Sign Feasibility Agreement to Develop AVERSA(TM) Fentanyl, an Abuse Deterrent Fentanyl Patch
By Nutriband Inc. · Via AccessWire · January 10, 2022
Nutriband Lead Product Aversa(TM) Fentanyl May Reach Peak Annual Sales of $80-200 Million Based on Market Assessment by Leading Healthcare Consulting Firm
By Nutriband Inc. · Via AccessWire · January 5, 2022
Nutriband Inc. Issued Full Patent from the Korean Intellectual Property Office for Its "Abuse and Misuse Deterrent Transdermal System" Application
By Nutriband Inc. · Via AccessWire · December 31, 2021
Nutriband Inc. Announces $1 Million Share Repurchase Authorization
By Nutriband Inc. · Via AccessWire · December 29, 2021
Nutriband Inc. Initiates Plans to Offer Topical Lotion Contract Manufacturing Services
By Nutriband Inc. · Via AccessWire · December 21, 2021
Nutriband Inc. Receives cGMP Certification for Manufacturing Subsidiary
By Nutriband Inc. · Via AccessWire · December 13, 2021
Nutriband Inc. to Ring NASDAQ Stock Market Opening Bell on December 3, 2021
By Nutriband Inc. · Via AccessWire · December 3, 2021
Nutriband Inc. Initiates Commercial Development of Lead Product AVERSA(TM) Fentanyl
By Nutriband Inc. · Via AccessWire · November 16, 2021
Nutriband Inc. Interview to Air on Bloomberg U.S. on the RedChip Money Report(R)
By Nutriband Inc. · Via AccessWire · November 10, 2021
Nutriband Inc. Receives Additional $2,062,500 from Exercise of Warrants, Increasing Total Capital from Public Offering and Nasdaq Listing to Approx. $8.7M
By Nutriband Inc. · Via AccessWire · October 22, 2021
Nutriband Inc. Signs Exclusive Manufacturing Agreement for Diocheck(TM) Visual COVID-19 Antibody Indicator Patch
By Nutriband Inc. · Via AccessWire · October 12, 2021
Nutriband Inc.'s AVERSA(R) technology receives Notice of Allowance from United States Patent and Trademark Office (USPTO)
By Nutriband Inc. · Via AccessWire · October 4, 2021